On Tuesday, Truist Securities adjusted its outlook on DaVita Inc . (NYSE: NYSE:DVA) shares, a leading provider of kidney care services. The firm increased the company's price target to $165 from the previous $150 while maintaining a Hold rating. The revision reflects updated earnings projections following the company's second-quarter results and revised full-year 2024 guidance.
The new price target comes after Truist Securities updated its earnings estimates for the upcoming years. The firm now expects DaVita to achieve adjusted earnings per share (EPS) of $9.72 in 2024, up from the prior estimate of $9.46. For the year 2025, the forecast has been raised to an adjusted EPS of $11.06, compared to the earlier prediction of $10.42.
The analyst at Truist Securities cited the second-quarter performance and the raised guidance for the full year 2024 as the basis for the updated estimates. The firm's decision to maintain the Hold rating suggests a neutral stance on the stock's current valuation and future prospects.
Investors and market watchers will be observing how DaVita's stock responds to the revised price target and earnings expectations. The company's performance in the coming quarters will be a key factor in determining whether the stock can reach or surpass the new price target set by Truist Securities.
The updated financial outlook for DaVita provides a clearer picture for shareholders regarding the company's expected performance in the near term.
With the price target now set at $165, market participants have a new benchmark against which to measure the company's progress and investment potential.
InvestingPro Insights
DaVita Inc. (NYSE: DVA), recognized for its proficiency in kidney care services, is demonstrating a robust financial performance with a market capitalization of $12.77 billion. The company's commitment to returning value to shareholders is evident through an aggressive share buyback strategy, as highlighted by one of the InvestingPro Tips. Moreover, DaVita's trading dynamics present a low P/E ratio of 15.64, which becomes even more attractive when considering the near-term earnings growth, with an adjusted P/E ratio for the last twelve months as of Q2 2024 at 14.77.
The financial strength of DaVita is further supported by a strong free cash flow yield, as indicated by another InvestingPro Tip, and a solid revenue growth of 6.69% over the last twelve months as of Q2 2024. While the company does not currently pay a dividend, its shareholder yield is considered high due to the share repurchases and the potential for capital gains, as the stock is trading near its 52-week high, with a price percentage of 99.97% of that peak.
For investors seeking more comprehensive insights, there are over ten additional InvestingPro Tips available, which delve into aspects such as DaVita's valuation, profitability, and stock performance. These tips, along with the real-time data provided, are designed to offer a deeper understanding of the company's financial health and market position, which could be crucial for making informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.